Investing in ambitious life science businesses
Discovery Park Ventures is our very own investment fund, keen on supporting and mentoring exciting innovators with novel business ideas.
Launched in May 2022, Discovery Park Ventures is an investment fund that invests in ambitious and growing life sciences companies, driving disruptive innovation and catalysing economic growth.
Investing on behalf of private individuals, the £3m fund supports exciting early-stage companies at start-up or to help them leverage non-dilutive funding and has plans to expand to up to £25m in the next three years.
The fund isn’t guaranteed to occupiers of Discovery Park, though our supportive team are always ready to open doors and make connections into other investment opportunities and networks where possible. Similarly, investee companies do not necessarily need to be based at Discovery Park but are likely to have a strong collaborative relationship.
£3m investment fund for early-stage innovators
Experienced team to mentor and guide
Access to wider network of experts
Focus on disruptive technologies
Oxford Medical Products
Discovery Park Ventures is a very welcome addition to our investor base. With Sirona in clinical trials this is an exciting stage of development for Oxford Medical Products and we look forward to working with the DPV team as we progress towards the market.
Dr Camilla Easter , CEO of Oxford Medical Products
We are delighted to be backed by Discovery Park Ventures. Its team’s extensive experience of company building, business development and fundraising will be invaluable to Ignota Labs as we create partnerships around our toxicity screening technology and build our offering.
Sam Windsor , CEO of Ignota Labs
We’re delighted to welcome Discovery Park Ventures as a new investor as we enter this exciting clinical phase of development. As a Discovery Park tenant we have found the environment very supportive and this investment is another way in which the Park is driving our growth.
Dr Joanna Gould , CEO, VisusNano
We’d like to thank Discovery Park Ventures for its belief in our innovative approach to cancer treatment and therapeutic delivery, and welcome it as a shareholder. Vitarka Therapeutics looks forward to working with DPV as we generate our proof of concept data3.